구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | axicabtagene ciloleucel (Yescarta, axi-cel) Kite / Gilead·CD19 68 trials·t½ CAR T expansion peak ~7–14 days post-infusion; persistence months in responders |
|---|---|
Overview Program | Yescarta (axicabtagene ciloleucel) |
Overview Company | Kite / Gilead |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | LBCL, FL |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Rapid manufacturing, CD28 signaling |
Positioning Known limitation | CD19 antigen loss, T-cell exhaustion, and hostile tumor microenvironment. |
Positioning Development positioning | First mover in CD19 CAR-T LBCL |
Technology Vector | Retrovirus |
MoA Mechanism | Autologous T cells transduced with a retroviral vector encoding an anti-CD19 CAR (scFv + CD28 + CD3ζ). CAR T cells expand in vivo, recognize CD19 on B cells, and mediate cytotoxic killing. |
MoA Biomarker | CD19 expression on lymphoma cells; CAR T expansion in blood. |
PK/PD Half-life | CAR T expansion peak ~7–14 days post-infusion; persistence months in responders |
PK/PD Species | resistance, toxicity, and precision strategies., CAR T copy number in blood, B-cell aplasia |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacodynamic |
Toxicology Species | resistance, toxicity, and precision strategies. |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | CRS, ICANS, cytopenias |
Toxicology CRS | Grade ≥3 ~13% |
Clinical Safety signal | CRS, ICANS, cytopenias |
Clinical Selected reported efficacy | ORR 92% |
Clinical Reported ORR | 94% |
Clinical Reported PFS | 40.2 |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03105336 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03105336 |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | axicabtagene ciloleucel (Yescarta, axi-cel) Kite / Gilead·CD19 68 trials·t½ CAR T expansion peak ~7–14 days post-infusion; persistence months in responders |
|---|---|
Overview Program | Yescarta (axicabtagene ciloleucel) |
Overview Company | Kite / Gilead |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | LBCL, FL |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Rapid manufacturing, CD28 signaling |
Positioning Known limitation | CD19 antigen loss, T-cell exhaustion, and hostile tumor microenvironment. |
Positioning Development positioning | First mover in CD19 CAR-T LBCL |
Technology Vector | Retrovirus |
MoA Mechanism | Autologous T cells transduced with a retroviral vector encoding an anti-CD19 CAR (scFv + CD28 + CD3ζ). CAR T cells expand in vivo, recognize CD19 on B cells, and mediate cytotoxic killing. |
MoA Biomarker | CD19 expression on lymphoma cells; CAR T expansion in blood. |
PK/PD Half-life | CAR T expansion peak ~7–14 days post-infusion; persistence months in responders |
PK/PD Species | resistance, toxicity, and precision strategies., CAR T copy number in blood, B-cell aplasia |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacodynamic |
Toxicology Species | resistance, toxicity, and precision strategies. |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | CRS, ICANS, cytopenias |
Toxicology CRS | Grade ≥3 ~13% |
Clinical Safety signal | CRS, ICANS, cytopenias |
Clinical Selected reported efficacy | ORR 92% |
Clinical Reported ORR | 94% |
Clinical Reported PFS | 40.2 |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03105336 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03105336 |
추천 비교
추천 비교